GSK Seeking Regulatory Approval for Long-Term Asthma Treatment in EU, Japan and China

MT Newswires Live

Jan 28, 2025

GSK (GSK) said Tuesday that regulators in Europe, Japan and China have accepted separate applications to review its depemokimab drug candidate for a pair of asthma indications, including as an add-on treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps.

The company said it is also seeking approval to market the monoclonal antibody as a maintenance add-on therapy for type 2 inflammation with an eosinophilic phenotype in patients aged 12 and up whose asthma is inadequately controlled by corticosteroids.

GSK said that if approved, depemokimab will be the first ultra-long-acting biologic with six-month dosing and that it is not currently approved in any jurisdiction.

Price: 35.53, Change: +0.03, Percent Change: +0.08

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2506511777"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2506511777\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2506511777?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-28 22:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2506511777","market":"us","top_or_hot":-1,"title":"GSK Seeking Regulatory Approval for Long-Term Asthma Treatment in EU, Japan and China","media":"MT Newswires Live","content":"<html><body><p> GSK (GSK) said Tuesday that regulators in Europe, Japan and China have accepted separate applications to review its depemokimab drug candidate for a pair of asthma indications, including as an add-on treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps.</p><p>The company said it is also seeking approval to market the monoclonal antibody as a maintenance add-on therapy for type 2 inflammation with an eosinophilic phenotype in patients aged 12 and up whose asthma is inadequately controlled by corticosteroids.</p><p>GSK said that if approved, depemokimab will be the first ultra-long-acting biologic with six-month dosing and that it is not currently approved in any jurisdiction.</p><p>Price: 35.53, Change: +0.03, Percent Change: +0.08</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Seeking Regulatory Approval for Long-Term Asthma Treatment in EU, Japan and China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Seeking Regulatory Approval for Long-Term Asthma Treatment in EU, Japan and China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-28 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> GSK (GSK) said Tuesday that regulators in Europe, Japan and China have accepted separate applications to review its depemokimab drug candidate for a pair of asthma indications, including as an add-on treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps.</p><p>The company said it is also seeking approval to market the monoclonal antibody as a maintenance add-on therapy for type 2 inflammation with an eosinophilic phenotype in patients aged 12 and up whose asthma is inadequately controlled by corticosteroids.</p><p>GSK said that if approved, depemokimab will be the first ultra-long-acting biologic with six-month dosing and that it is not currently approved in any jurisdiction.</p><p>Price: 35.53, Change: +0.03, Percent Change: +0.08</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2506511777","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2506511777","pubTimestamp":1738075438,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"GSK (GSK) said Tuesday that regulators in Europe, Japan and China have accepted separate applications to review its depemokimab drug candidate for a pair of asthma indications, including as an add-on ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","GSK":"葛兰素史克","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4588":"碎股","BK4532":"文艺复兴科技持仓","BK4007":"制药","GSK.UK":"葛兰素史克","BK4156":"煤与消费用燃料"},"translate_title":"葛兰素史克寻求欧盟、日本和中国监管机构批准长期哮喘治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":0.6,"GSK":1},"content_text":"GSK (GSK) said Tuesday that regulators in Europe, Japan and China have accepted separate applications to review its depemokimab drug candidate for a pair of asthma indications, including as an add-on treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps.The company said it is also seeking approval to market the monoclonal antibody as a maintenance add-on therapy for type 2 inflammation with an eosinophilic phenotype in patients aged 12 and up whose asthma is inadequately controlled by corticosteroids.GSK said that if approved, depemokimab will be the first ultra-long-acting biologic with six-month dosing and that it is not currently approved in any jurisdiction.Price: 35.53, Change: +0.03, Percent Change: +0.08","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}